Results

Since the implementation of the workflow in February 2022, 5 patients have been identified. All patients received neurology consultation within 24 hours of presentation, after which 3 underwent diagnostic evaluation for AE.

Conclusions

The implementation of a multi-disciplinary clinical workflow to triage patients presenting with AP is feasible. Preliminary evidence suggests a significant decrease in time from presentation to diagnostic evaluation for AE compared to the time prior to its implementation.

Disclosure: Dr. Russo has nothing to disclose. Dr. Noy has nothing to disclose. Dr. Stojanovic has nothing to disclose. Dr. Thakur has received personal compensation for serving as an employee of World Health Organization. The institution of Dr. Thakur has received research support from Center for Disease Control and Prevention. The institution of Dr. Thakur has received research support from National Institute of Health. The institution of Dr. Thakur has received research support from Biomerieux.

References

1. Herken J., & Prüss H. (2017) Red flags: Clinical signs for identifying autoimmune encephalitis in psychiatric patients. *Frontiers in Psychiatry*, 8. 25, https://doi.org/10.3389/fpsyt.2017.00025
2. Pollak T. A., et al. (2020). Autoimmune psychosis: An international consensus on an approach to the diagnosis and management of psychosis of suspected autoimmune origin. *The Lancet Psychiatry*, 7(1), 93-108. https://doi.org/10.1016/s2215-0366(19)30290-13. Herken et al. (2017)
3. Herken, et al. (2017).

Two Cases of Isolated Neurofilament Heavy Chain Antibody Syndrome

Alexander Mirzoev

Objective

Novel clinical and laboratory findings in anti-neurofilament heavy chain encephalitis

Background

Antibodies to mature components of neuronal intermediate filament (NIF) have been implicated in several neurological disorders, including multiple sclerosis, amyotrophic lateral sclerosis, and more recently, various autoimmune encephalitides. The components include a-internexin, light chain and heavy chain. In the largest case series of anti-NIF syndromes (McKeon et al, 2021), patients' cell-based assays revealed antibodies to one, two or all three components. Heavy chain antibodies (anti-NfH) were present in most, including three out of four patients with encephalopathy and cerebellar involvement. One was due to a paraneoplastic phenomenon. Anti-NfH was also elevated in two cases of encephalopathy with spasticity. It was the lone autoantibody in one of the six aforementioned cases.

Design/Methods

N/A.

Results

Case 1: 37-year old female with a history of ovarian carcinoma, treated in 2016. Cognitive impairment started in fall 2019, with significant worsening to the point of catatonia and coma in October 2020. Though encephalopathy improved, severe ataxia and nystagmus persisted. Two MRI brain studies and an EEG were unremarkable, and no radiological evidence of cancer recurrence. Oligoclonal bands (in both CSF and serum) and serum anti-NfH were elevated. Case 2: 59 year-old female with gradual cognitive decline since March 2018, followed by rapid cognitive deterioration in Oct 2020. There was limb weakness, severe rigidity, clonus and a witnessed seizure. EEG showed intermittent rhythmic delta activity. MRI brain indicated severe bilateral hippocampal atrophy. CSF Protein and CSF anti-NfH were elevated.

Conclusions

This case series contains the first reported paraneoplastic encephalopathy with cerebellar involvement from isolated anti-NfH. Also presented is the first reported case of PERMS from any NIF antibody. Further research is needed on quantitative and qualitative factors of anti-NIF syndromes. Specifically, the clinical relevance of the number of antibodies, and associations between phenotype and specific antibody combination.

Disclosure: Dr. Mirzoev has nothing to disclose.

False Positive Cerebrospinal Fluid NMDA Receptor Antibodies: A Single Center Case Series

Rumyar Ardakani, Steven Vernino, Kyle Blackburn

Objective

To report the presence of CSF NMDA receptor antibodies in four patients without NMDA receptor encephalitis encountered at a single tertiary care center.

Background

The diagnosis and confirmation of anti-NMDA encephalitis relies heavily on detection of IgG antibodies to the NR1 subunit of the NMDA receptor in cerebrospinal fluid. While this is generally considered a highly specific test for anti-NMDA encephalitis, there have been rare reports of false positive testing.

Design/Methods

A retrospective chart review of medical records for patients with positive CSF NMDA receptor antibody testing at University of Texas Southwestern Medical Center between 2011 to 2021 was performed.

Results

40 patients were identified who had positive CSF NMDA receptor antibodies. Of these 40 patients, 4 (10%) were concluded to have false positive results. The false positive results consisted of 1 patient with refractory status epilepticus from suspected synthetic cannabinoid use, 1 patient with an anaplastic astrocytoma, 1 patient with fungal meningitis from Candida dubliniensis, and 1 patient with bifrontal cerebritis of suspected infectious etiology. Of the 4 patients with false positive antibody testing, 3 were immediately recognized as likely false positives while 1 patient was misdiagnosed and treated for an autoimmune encephalitis prior to a final diagnosis with tissue biopsy.

Conclusions

Although uncommon, false positive CSF NMDA receptor antibodies pose significant diagnostic and therapeutic challenges for clinicians. In our case series, false positive tests occurred in patients with apparent central nervous system disorders, including seizure, infection, and neoplasm. While antibody testing is an essential tool for the diagnosis of NMDA receptor encephalitis, caution should be exercised in interpreting positive results when the clinical and paraclinical data are not consistent with the well characterized phenotype of NMDA receptor encephalitis.

Disclosure: Dr. Ardakani has nothing to disclose. Dr. Vernino has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amneal. Dr. Vernino has received personal compensation in the range of $500-$4,999 for serving as a Consultant for argenx. Dr. Vernino has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Vernino has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alterity. Dr. Vernino has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for LabCorp. The institution of Dr. Vernino has received research support from Grifols. The institution of Dr. Vernino has received research support from Dysautonomia International. The institution of Dr. Vernino has received research

Two Cases of Isolated Neurofilament Heavy Chain Antibody Syndrome

Alexander Mirzoev

Neurology 2022;99;S54
DOI 10.1212/01.wnl.0000903436.03488.75